南美超级胎牛血清999尝鲜特惠
转染试剂低至5折
基质胶阶梯特惠
积分商城,好礼送不停
南美超级胎牛血清999尝鲜特惠
转染试剂低至5折
基质胶阶梯特惠
积分商城,好礼送不停

Cx26在线粒体中的定位促进结直肠癌恶性进展,并暴露出药物靶向治疗的致命弱点

Mitochondrial Localization of Cx26 Promotes Colorectal Cancer Malignancy and Exposes a Fatal Vulnerability to Drug Targeting

Jie Wang, Lu Chen, Jia Qin, Xiaoning Wang, Sunlan Ye, Ning An, Mei Bai, Yan Shen, Xuefeng Wu, Qiang Xu

Journal:Advanced Science

IF:14.1

DOI:10.1002/advs.78117

PMID:42815004

Published:2026-09-30

research field:细胞生物学遗传学与基因组学

Abstract

The malignant progression of colorectal cancer (CRC) is closely linked to metastasis and therapy resistance, but underlying mechanisms remain unclear. Here, we identify mitochondrial translocation of connexin 26 (Cx26) as a hallmark of highly malignant metastatic CRC and reveal its critical role in promoting ER‐mitochondria crosstalk, calcium signaling, and epithelial‐mesenchymal transition (EMT). Mechanistically, we demonstrate that protein L‐isoaspartyl/D‐aspartyl O‐methyltransferase (PIMT) methylates Cx26 at asparagine 176, enhancing its mitochondrial localization and stability. This modification disrupts Cx26's gap junction function while activating calcium signaling to drive EMT and metastasis. Furthermore, we discovered that bortezomib (BTZ), contrary to its canonical proteasome inhibition mechanism, exhibits exceptional efficacy against highly malignant CRC by targeting the PIMT‐Cx26 axis. BTZ directly binds PIMT, further amplifying Cx26 mitochondrial translocation and hyperactivating Ca 2 + ‐ROS‐ERK signaling, ultimately inducing lethal autophagy and apoptosis in metastatic CRC cells. Strikingly, low‐malignancy primary CRC cells remain resistant to BTZ, highlighting its selectivity for advanced disease. Collectively, our study uncovers mitochondrial Cx26 as a novel therapeutic vulnerability in metastatic CRC and repurposes BTZ as a precision strategy targeting PIMT. Mitochondrial localization of Cx26 emerges as a double‐edged sword in colorectal cancer. PIMT‐mediated methylation of Cx26 promotes its mitochondrial localization and stability. Mitochondrial Cx26 then facilitates ER‐mitochondria communication and Ca 2+ signaling, thereby promoting metastatic progression. Bortezomib exploits this malignant adaptation by further amplifying the PIMT‐Cx26 interaction, triggering excessive Ca 2+ ‐ROS‐ERK signaling and ultimately inducing autophagy and apoptosis, thereby converting a metastatic advantage into a therapeutic vulnerability.

本文使用的Yeasen产品

购物车
客服
转染试用